Utomilumab
drugOn this page
Also known as PF-05082566PF-5082566
Summary
Utomilumab (CHEMBL3707324) is a phase-3 clinical-stage antibody targeting TNFRSF9; indicated across 10 conditions including diffuse large b-cell lymphoma and breast neoplasm.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Targets: 1 (TNFRSF9)
- Indications: 10 conditions
- Clinical trials: 16
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL3707324 |
| Name | Utomilumab |
| Type | Antibody |
| Max phase | 3 |
Also known as: PF-05082566, PF-5082566, Utomilumab, UTOMILUMAB
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| TNFRSF9 | 4-1BB | Agonist | 8.06 | 0.2% | Q07011 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): TNFRSF9.
Top Reactome pathways
1 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| TNFs bind their physiological receptors | 1 | TNFRSF9 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| apoptotic process | 1 |
| negative regulation of cell population proliferation | 1 |
| regulation of immature T cell proliferation in thymus | 1 |
| regulation of cell population proliferation | 1 |
Indications & clinical
Indications
10 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| diffuse large B-cell lymphoma | 3 | MONDO:0018905 | EFO:0000403 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| triple-negative breast carcinoma | 2 | MONDO:0005494 | EFO:0005537 |
| HER2 positive breast carcinoma | 2 | MONDO:0006244 | EFO:1000294 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
| ovarian carcinoma | 1 | MONDO:0005140 | EFO:0001075 |
| metastatic prostate carcinoma | 1 | MONDO:0004956 | EFO:0000196 |
| follicular lymphoma | 1 | MONDO:0018906 | MONDO:0018906 |
| neoplasm of mature B-cells | 1 | MONDO:0004949 | EFO:0000096 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 16.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 8 |
| PHASE1/PHASE2 | 3 |
| PHASE2 | 3 |
| PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05059522 | PHASE3 | ACTIVE_NOT_RECRUITING | Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing |
| NCT02951156 | PHASE3 | TERMINATED | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) |
| NCT03217747 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies |
| NCT03414658 | PHASE2 | ACTIVE_NOT_RECRUITING | The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer |
| NCT03971409 | PHASE2 | ACTIVE_NOT_RECRUITING | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer |
| NCT02554812 | PHASE1/PHASE2 | TERMINATED | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) |
| NCT03258008 | PHASE2 | TERMINATED | Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer |
| NCT03318900 | PHASE1/PHASE2 | COMPLETED | T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer |
| NCT01307267 | PHASE1 | COMPLETED | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab |
| NCT02179918 | PHASE1 | COMPLETED | A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036) |
| NCT02444793 | PHASE1 | TERMINATED | A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors |
| NCT03290937 | PHASE1 | COMPLETED | Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer |
| NCT03364348 | PHASE1 | COMPLETED | 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer |
| NCT03440567 | PHASE1 | COMPLETED | Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma |
| NCT03636503 | PHASE1 | TERMINATED | Rituximab + Immunotherapy in Follicular Lymphoma |
| NCT03704298 | PHASE1 | TERMINATED | Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Genes: TNFRSF9
- Diseases: diffuse large B-cell lymphoma